Context Therapeutics Inc.
NASDAQ:CNTXBiotechnology
+$0.02 today
- Market cap
- $63.67M
- Beta
- 1.61
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.42
Volume 1.71M
Average 1.16M
CNTX Debt Repayment
Cash used to repay borrowings during the period.
Context Therapeutics Inc.NASDAQ: CNTX
Debt Repayment · Q1 FY2026 · quarter ended Mar 2026
Debt repayment outflow grows to $0
Q1 FY2026 debt repayment was $0, compared with $0 a year earlier. Trailing-twelve-month debt repayment was $0.
Context
- Debt repayment increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly debt repayment holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Debt Repayment history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Debt Repayment | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Debt Repayment vs competitors
How CNTX compares with its peers on the latest reported figures
- Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
IMAImageneBio Inc | LTM Mar 2026 | $15M USD | — | — | — |
| LTM Mar 2026 | $10.36M USD | -66.1% | — | — | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $7.5M USD | — | +20.4% | — |
| LTM Mar 2026 | $90K USD | -99.2% | -41.4% | 67.2% | |
| LTM Mar 2026 | €25.41K EUR | +106.3% | -0.6% | 86.6% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $0 USD | — | — | 0.0% |
| FY2025 | $0 USD | — | — | 0.0% | |
| Peer median (excluding CNTX) | — | -66.1% | -0.6% | 0.0% | |
Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (10.46M) | (14.84M) | (23.96M) | (26.73M) | (36.12M) |
| Depreciation & Amortization | 0 | 9.27K | 12.04K | 10.88K | 16.25K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 511.08K | 976.44K | 1.08M | 841.87K | 1.33M |
| Change in Working Capital | (2.22M) | (277.52K) | 1.78M | (3.48M) | 6.28M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (866.01K) | (787.89K) | 1.45M | (946K) | 1.1M |
| Other Working Capital | (1.36M) | 510.37K | 329.03K | (2.53M) | 5.19M |
| Other Non-Cash Items | 3.37M | 578.52K | 51.97K | 14.79M | 2.11M |
| Operating Cash Flow | (8.8M) | (13.55M) | (21.05M) | (14.56M) | (26.39M) |
| Capital Expenditures | (250K) | (536.84K) | 0 | (14.76M) | (33.95K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | (14.75M) | (2M) |
| Investing Cash Flow | (250K) | (536.84K) | 0 | (14.76M) | (2.03M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 53.41M | (102.07K) | 0 | 109.29M | (15.27K) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 58.39M | (102.07K) | 0 | 109.29M | (15.27K) |
| Effect of Forex Changes | 0 | 50.39K | 0 | 0 | 0 |
| Net Change in Cash | 49.34M | (14.14M) | (21.05M) | 79.98M | (28.43M) |
| Free Cash Flow | (9.05M) | (14.09M) | (21.05M) | (29.31M) | (26.42M) |
Context Therapeutics Inc.
NASDAQ:CNTX
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.